On the SMMT site, it appears they will start clinical trials in the 2nd quarter of this year.
Two things:
- It isn’t clear to me how much Summit can use Chinese drug data. This is on the Summit site: "Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
It is currently being investigated in Phase III clinical studies."
But it is designated as a breakthrough therapy in China. I haven’t tried to reconcile these statements.
- They presented at the JPM Healthcare Conference that wrapped up this week. I have not yet found their presentation… which I suspect would be pretty important.
Rob
He is no fool who gives what he cannot keep to gain what he cannot lose.